1
|
Allerton CMN, Arcari JT, Aschenbrenner LM, Avery M, Bechle BM, Behzadi MA, Boras B, Buzon LM, Cardin RD, Catlin NR, Carlo AA, Coffman KJ, Dantonio A, Di L, Eng H, Farley KA, Ferre RA, Gernhardt SS, Gibson SA, Greasley SE, Greenfield SR, Hurst BL, Kalgutkar AS, Kimoto E, Lanyon LF, Lovett GH, Lian Y, Liu W, Martínez Alsina LA, Noell S, Obach RS, Owen DR, Patel NC, Rai DK, Reese MR, Rothan HA, Sakata S, Sammons MF, Sathish JG, Sharma R, Steppan CM, Tuttle JB, Verhoest PR, Wei L, Yang Q, Yurgelonis I, Zhu Y. A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19. J Med Chem 2024. [PMID: 38687966 DOI: 10.1021/acs.jmedchem.3c02469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2024]
Abstract
Despite the record-breaking discovery, development and approval of vaccines and antiviral therapeutics such as Paxlovid, coronavirus disease 2019 (COVID-19) remained the fourth leading cause of death in the world and third highest in the United States in 2022. Here, we report the discovery and characterization of PF-07817883, a second-generation, orally bioavailable, SARS-CoV-2 main protease inhibitor with improved metabolic stability versus nirmatrelvir, the antiviral component of the ritonavir-boosted therapy Paxlovid. We demonstrate the in vitro pan-human coronavirus antiviral activity and off-target selectivity profile of PF-07817883. PF-07817883 also demonstrated oral efficacy in a mouse-adapted SARS-CoV-2 model at plasma concentrations equivalent to nirmatrelvir. The preclinical in vivo pharmacokinetics and metabolism studies in human matrices are suggestive of improved oral pharmacokinetics for PF-07817883 in humans, relative to nirmatrelvir. In vitro inhibition/induction studies against major human drug metabolizing enzymes/transporters suggest a low potential for perpetrator drug-drug interactions upon single-agent use of PF-07817883.
Collapse
Affiliation(s)
| | - Joel T Arcari
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | | | - Melissa Avery
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | - Bruce M Bechle
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | | | - Britton Boras
- Pfizer Research & Development, La Jolla, California 92121, United States
| | - Leanne M Buzon
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | - Rhonda D Cardin
- Pfizer Research & Development, Pearl River, New York 10965, United States
| | - Natasha R Catlin
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | - Anthony A Carlo
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | - Karen J Coffman
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | - Alyssa Dantonio
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | - Li Di
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | - Heather Eng
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | - Kathleen A Farley
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | - Rose Ann Ferre
- Pfizer Research & Development, La Jolla, California 92121, United States
| | | | - Scott A Gibson
- Institute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah 84322, United States
| | | | | | - Brett L Hurst
- Institute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah 84322, United States
| | - Amit S Kalgutkar
- Pfizer Research & Development, Cambridge, Massachusetts 02139, United States
| | - Emi Kimoto
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | - Lorraine F Lanyon
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | - Gabrielle H Lovett
- Pfizer Research & Development, Cambridge, Massachusetts 02139, United States
| | - Yajing Lian
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | - Wei Liu
- Pfizer Research & Development, La Jolla, California 92121, United States
| | | | - Stephen Noell
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | - R Scott Obach
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | - Dafydd R Owen
- Pfizer Research & Development, Cambridge, Massachusetts 02139, United States
| | - Nandini C Patel
- Pfizer Research & Development, Cambridge, Massachusetts 02139, United States
| | - Devendra K Rai
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | - Matthew R Reese
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | - Hussin A Rothan
- Pfizer Research & Development, Pearl River, New York 10965, United States
| | - Sylvie Sakata
- Pfizer Research & Development, La Jolla, California 92121, United States
| | - Matthew F Sammons
- Pfizer Research & Development, Cambridge, Massachusetts 02139, United States
| | - Jean G Sathish
- Pfizer Research & Development, Pearl River, New York 10965, United States
| | - Raman Sharma
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | - Claire M Steppan
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | - Jamison B Tuttle
- Pfizer Research & Development, Cambridge, Massachusetts 02139, United States
| | - Patrick R Verhoest
- Pfizer Research & Development, Cambridge, Massachusetts 02139, United States
| | - Liuqing Wei
- Pfizer Research & Development, Groton, Connecticut 06340, United States
| | - Qingyi Yang
- Pfizer Research & Development, Cambridge, Massachusetts 02139, United States
| | - Irina Yurgelonis
- Pfizer Research & Development, Pearl River, New York 10965, United States
| | - Yuao Zhu
- Pfizer Research & Development, Pearl River, New York 10965, United States
| |
Collapse
|
2
|
Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, Boras B, Cardin RD, Carlo A, Coffman KJ, Dantonio A, Di L, Eng H, Ferre R, Gajiwala KS, Gibson SA, Greasley SE, Hurst BL, Kadar EP, Kalgutkar AS, Lee JC, Lee J, Liu W, Mason SW, Noell S, Novak JJ, Obach RS, Ogilvie K, Patel NC, Pettersson M, Rai DK, Reese MR, Sammons MF, Sathish JG, Singh RSP, Steppan CM, Stewart AE, Tuttle JB, Updyke L, Verhoest PR, Wei L, Yang Q, Zhu Y. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19. Science 2021; 374:1586-1593. [PMID: 34726479 DOI: 10.1126/science.abl4784] [Citation(s) in RCA: 931] [Impact Index Per Article: 310.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
[Figure: see text].
Collapse
Affiliation(s)
- Dafydd R Owen
- Pfizer Worldwide Research, Development & Medical, Cambridge, MA 02139, USA
| | | | | | | | - Melissa Avery
- Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA
| | - Simon Berritt
- Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA
| | - Britton Boras
- Pfizer Worldwide Research, Development & Medical, La Jolla, CA 92121, USA
| | - Rhonda D Cardin
- Pfizer Worldwide Research, Development & Medical, Pearl River, NY 10965, USA
| | - Anthony Carlo
- Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA
| | - Karen J Coffman
- Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA
| | - Alyssa Dantonio
- Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA
| | - Li Di
- Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA
| | - Heather Eng
- Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA
| | - RoseAnn Ferre
- Pfizer Worldwide Research, Development & Medical, La Jolla, CA 92121, USA
| | - Ketan S Gajiwala
- Pfizer Worldwide Research, Development & Medical, La Jolla, CA 92121, USA
| | - Scott A Gibson
- Institute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University; Logan, UT 84322, USA
| | | | - Brett L Hurst
- Institute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University; Logan, UT 84322, USA
| | - Eugene P Kadar
- Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA
| | - Amit S Kalgutkar
- Pfizer Worldwide Research, Development & Medical, Cambridge, MA 02139, USA
| | - Jack C Lee
- Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA
| | - Jisun Lee
- Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA
| | - Wei Liu
- Pfizer Worldwide Research, Development & Medical, La Jolla, CA 92121, USA
| | - Stephen W Mason
- Pfizer Worldwide Research, Development & Medical, Pearl River, NY 10965, USA
| | - Stephen Noell
- Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA
| | - Jonathan J Novak
- Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA
| | - R Scott Obach
- Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA
| | - Kevin Ogilvie
- Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA
| | - Nandini C Patel
- Pfizer Worldwide Research, Development & Medical, Cambridge, MA 02139, USA
| | - Martin Pettersson
- Pfizer Worldwide Research, Development & Medical, Cambridge, MA 02139, USA
| | - Devendra K Rai
- Pfizer Worldwide Research, Development & Medical, Pearl River, NY 10965, USA
| | - Matthew R Reese
- Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA
| | - Matthew F Sammons
- Pfizer Worldwide Research, Development & Medical, Cambridge, MA 02139, USA
| | - Jean G Sathish
- Pfizer Worldwide Research, Development & Medical, Pearl River, NY 10965, USA
| | | | - Claire M Steppan
- Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA
| | - Al E Stewart
- Pfizer Worldwide Research, Development & Medical, La Jolla, CA 92121, USA
| | - Jamison B Tuttle
- Pfizer Worldwide Research, Development & Medical, Cambridge, MA 02139, USA
| | - Lawrence Updyke
- Pfizer Worldwide Research, Development & Medical, Cambridge, MA 02139, USA
| | - Patrick R Verhoest
- Pfizer Worldwide Research, Development & Medical, Cambridge, MA 02139, USA
| | - Liuqing Wei
- Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA
| | - Qingyi Yang
- Pfizer Worldwide Research, Development & Medical, Cambridge, MA 02139, USA
| | - Yuao Zhu
- Pfizer Worldwide Research, Development & Medical, Pearl River, NY 10965, USA
| |
Collapse
|
3
|
Seneviratne U, Huang Z, Am Ende CW, Butler TW, Cleary L, Dresselhaus E, Evrard E, Fisher EL, Green ME, Helal CJ, Humphrey JM, Lanyon LF, Marconi M, Mukherjee P, Sciabola S, Steppan CM, Sylvain EK, Tuttle JB, Verhoest PR, Wager TT, Xie L, Ramaswamy G, Johnson DS, Pettersson M. Photoaffinity Labeling and Quantitative Chemical Proteomics Identify LXRβ as the Functional Target of Enhancers of Astrocytic apoE. Cell Chem Biol 2020; 28:148-157.e7. [PMID: 32997975 DOI: 10.1016/j.chembiol.2020.09.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Revised: 04/17/2020] [Accepted: 09/04/2020] [Indexed: 12/25/2022]
Abstract
Utilizing a phenotypic screen, we identified chemical matter that increased astrocytic apoE secretion in vitro. We designed a clickable photoaffinity probe based on a pyrrolidine lead compound and carried out probe-based quantitative chemical proteomics in human astrocytoma CCF-STTG1 cells to identify liver x receptor β (LXRβ) as the target. Binding of the small molecule ligand stabilized LXRβ, as shown by cellular thermal shift assay (CETSA). In addition, we identified a probe-modified peptide by mass spectrometry and proposed a model where the photoaffinity probe is bound in the ligand-binding pocket of LXRβ. Taken together, our findings demonstrated that the lead chemical matter bound directly to LXRβ, and our results highlight the power of chemical proteomic approaches to identify the target of a phenotypic screening hit. Additionally, the LXR photoaffinity probe and lead compound described herein may serve as valuable tools to further evaluate the LXR pathway.
Collapse
Affiliation(s)
| | - Zhen Huang
- Pfizer Worldwide Research and Development, Cambridge, MA 02139, USA
| | | | - Todd W Butler
- Pfizer Worldwide Research and Development, Groton, CT 06340, USA
| | - Leah Cleary
- Pfizer Worldwide Research and Development, Groton, CT 06340, USA
| | | | - Edelweiss Evrard
- Pfizer Worldwide Research and Development, Cambridge, MA 02139, USA
| | - Ethan L Fisher
- Pfizer Worldwide Research and Development, Groton, CT 06340, USA
| | - Michael E Green
- Pfizer Worldwide Research and Development, Cambridge, MA 02139, USA
| | | | - John M Humphrey
- Pfizer Worldwide Research and Development, Groton, CT 06340, USA
| | | | - Michael Marconi
- Pfizer Worldwide Research and Development, Cambridge, MA 02139, USA
| | | | - Simone Sciabola
- Pfizer Worldwide Research and Development, Cambridge, MA 02139, USA
| | - Claire M Steppan
- Pfizer Worldwide Research and Development, Groton, CT 06340, USA
| | - Emily K Sylvain
- Pfizer Worldwide Research and Development, Cambridge, MA 02139, USA
| | - Jamison B Tuttle
- Pfizer Worldwide Research and Development, Cambridge, MA 02139, USA
| | | | - Travis T Wager
- Pfizer Worldwide Research and Development, Cambridge, MA 02139, USA
| | - Longfei Xie
- Pfizer Worldwide Research and Development, Groton, CT 06340, USA
| | | | | | - Martin Pettersson
- Pfizer Worldwide Research and Development, Cambridge, MA 02139, USA.
| |
Collapse
|
4
|
Helal CJ, Arnold EP, Boyden TL, Chang C, Chappie TA, Fennell KF, Forman MD, Hajos M, Harms JF, Hoffman WE, Humphrey JM, Kang Z, Kleiman RJ, Kormos BL, LaChapelle EA, Lee CW, Lu J, Maklad N, McDowell L, Mente S, O’Connor RE, Pandit J, Piotrowski M, Schmidt AW, Schmidt CJ, Ueno H, Verhoest PR, Yang EX. Correction to Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor. J Med Chem 2018; 61:3753. [DOI: 10.1021/acs.jmedchem.8b00475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
Stepan AF, Tran TP, Helal CJ, Brown MS, Chang C, O’Connor RE, De Vivo M, Doran SD, Fisher EL, Jenkinson S, Karanian D, Kormos BL, Sharma R, Walker GS, Wright AS, Yang EX, Brodney MA, Wager TT, Verhoest PR, Obach RS. Late-Stage Microsomal Oxidation Reduces Drug-Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189. ACS Med Chem Lett 2018; 9:68-72. [PMID: 29456790 PMCID: PMC5807869 DOI: 10.1021/acsmedchemlett.7b00343] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2017] [Accepted: 01/03/2018] [Indexed: 12/20/2022] Open
Abstract
![]()
Late-stage oxidation using liver
microsomes was applied to phosphodiesterase
2 inhibitor 1 to reduce its clearance by cytochrome P450
enzymes, introduce renal clearance, and minimize the risk for victim
drug–drug interactions. This approach yielded PF-06815189 (2) with improved physicochemical properties and a mixed metabolic
profile. This example highlights the importance of C–H diversification
methods to drug discovery.
Collapse
Affiliation(s)
- Antonia F. Stepan
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Tuan P. Tran
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Christopher J. Helal
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Maria S. Brown
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Cheng Chang
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Rebecca E. O’Connor
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Michael De Vivo
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Shawn D. Doran
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Ethan L. Fisher
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Stephen Jenkinson
- Pfizer Worldwide Research and Development, 10770 Science Center Drive, La Jolla, California 92121, United States
| | - David Karanian
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Bethany L. Kormos
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Raman Sharma
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Gregory S. Walker
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Ann S. Wright
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Edward X. Yang
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Michael A. Brodney
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Travis T. Wager
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Patrick R. Verhoest
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - R. Scott Obach
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
6
|
Helal CJ, Arnold E, Boyden T, Chang C, Chappie TA, Fisher E, Hajos M, Harms JF, Hoffman WE, Humphrey JM, Pandit J, Kang Z, Kleiman RJ, Kormos BL, Lee CW, Lu J, Maklad N, McDowell L, McGinnis D, O'Connor RE, O'Donnell CJ, Ogden A, Piotrowski M, Schmidt CJ, Seymour PA, Ueno H, Vansell N, Verhoest PR, Yang EX. Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate. J Med Chem 2018; 61:1001-1018. [PMID: 29293004 DOI: 10.1021/acs.jmedchem.7b01466] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Computational modeling was used to direct the synthesis of analogs of previously reported phosphodiesterase 2A (PDE2A) inhibitor 1 with an imidazotriazine core to yield compounds of significantly enhanced potency. The analog PF-05180999 (30) was subsequently identified as a preclinical candidate targeting cognitive impairment associated with schizophrenia. Compound 30 demonstrated potent binding to PDE2A in brain tissue, dose responsive mouse brain cGMP increases, and reversal of N-methyl-d-aspartate (NMDA) antagonist-induced (MK-801, ketamine) effects in electrophysiology and working memory models in rats. Preclinical pharmacokinetics revealed unbound brain/unbound plasma levels approaching unity and good oral bioavailability resulting in an average concentration at steady state (Cav,ss) predicted human dose of 30 mg once daily (q.d.). Modeling of a modified release formulation suggested that 25 mg twice daily (b.i.d.) could maintain plasma levels of 30 at or above targeted efficacious plasma levels for 24 h, which became part of the human clinical plan.
Collapse
Affiliation(s)
- Christopher J Helal
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Eric Arnold
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Tracey Boyden
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Cheng Chang
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Thomas A Chappie
- Pfizer Worldwide Research and Development , 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Ethan Fisher
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Mihaly Hajos
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - John F Harms
- Pfizer Worldwide Research and Development , 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - William E Hoffman
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - John M Humphrey
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jayvardhan Pandit
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Zhijun Kang
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Robin J Kleiman
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Bethany L Kormos
- Pfizer Worldwide Research and Development , 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Che-Wah Lee
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jiemin Lu
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Noha Maklad
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Laura McDowell
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Dina McGinnis
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Rebecca E O'Connor
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Christopher J O'Donnell
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Adam Ogden
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Mary Piotrowski
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Christopher J Schmidt
- Pfizer Worldwide Research and Development , 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Patricia A Seymour
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Hirokazu Ueno
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Nichole Vansell
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| | - Patrick R Verhoest
- Pfizer Worldwide Research and Development , 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Edward X Yang
- Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
7
|
Zhang L, Chen L, Beck EM, Chappie TA, Coelho RV, Doran SD, Fan KH, Helal CJ, Humphrey JM, Hughes Z, Kuszpit K, Lachapelle EA, Lazzaro JT, Lee C, Mather RJ, Patel NC, Skaddan MB, Sciabola S, Verhoest PR, Young JM, Zasadny K, Villalobos A. The Discovery of a Novel Phosphodiesterase (PDE) 4B-Preferring Radioligand for Positron Emission Tomography (PET) Imaging. J Med Chem 2017; 60:8538-8551. [DOI: 10.1021/acs.jmedchem.7b01050] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Lei Zhang
- Medicine
Design, Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Laigao Chen
- Clinical & Translational Imaging, Early Clinical Development, Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Elizabeth M. Beck
- Medicine
Design, Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Thomas A. Chappie
- Medicine
Design, Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Richard V. Coelho
- Bioimaging
Center, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Shawn D. Doran
- Medicine
Design, Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Kuo-Hsien Fan
- Bioimaging
Center, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Christopher J. Helal
- Medicine
Design, Medicinal Chemistry, Pfizer Inc., Groton, Connecticut 06340, United States
| | - John M. Humphrey
- Medicine
Design, Medicinal Chemistry, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Zoe Hughes
- Internal
Medicine Research Unit, Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Kyle Kuszpit
- Bioimaging
Center, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Erik A. Lachapelle
- Medicine
Design, Medicinal Chemistry, Pfizer Inc., Groton, Connecticut 06340, United States
| | - John T. Lazzaro
- Medicine
Design, Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Chewah Lee
- Medicine
Design, Medicinal Chemistry, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Robert J. Mather
- Internal
Medicine Research Unit, Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Nandini C. Patel
- Medicine
Design, Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Marc B. Skaddan
- Bioimaging
Center, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Simone Sciabola
- Medicine
Design, Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Patrick R. Verhoest
- Medicine
Design, Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Joseph M. Young
- Medicine
Design, Medicinal Chemistry, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Kenneth Zasadny
- Bioimaging
Center, Pfizer Inc., Groton, Connecticut 06340, United States
| | - Anabella Villalobos
- Medicinal
Synthesis Technologies, Pfizer Inc., Groton, Connecticut 06340, United States
| |
Collapse
|
8
|
Stepan AF, Claffey MM, Reese MR, Balan G, Barreiro G, Barricklow J, Bohanon MJ, Boscoe BP, Cappon GD, Chenard LK, Cianfrogna J, Chen L, Coffman KJ, Drozda SE, Dunetz JR, Ghosh S, Hou X, Houle C, Karki K, Lazzaro JT, Mancuso JY, Marcek JM, Miller EL, Moen MA, O'Neil S, Sakurada I, Skaddan M, Parikh V, Smith DL, Trapa P, Tuttle JB, Verhoest PR, Walker DP, Won A, Wright AS, Whritenour J, Zasadny K, Zaleska MM, Zhang L, Shaffer CL. Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates. J Med Chem 2017; 60:7764-7780. [PMID: 28817277 DOI: 10.1021/acs.jmedchem.7b00604] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We previously observed a cutaneous type IV immune response in nonhuman primates (NHP) with the mGlu5 negative allosteric modulator (NAM) 7. To determine if this adverse event was chemotype- or mechanism-based, we evaluated a distinct series of mGlu5 NAMs. Increasing the sp3 character of high-throughput screening hit 40 afforded a novel morpholinopyrimidone mGlu5 NAM series. Its prototype, (R)-6-neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894, 8), possessed favorable properties and a predicted low clinical dose (2 mg twice daily). Compound 8 did not show any evidence of immune activation in a mouse drug allergy model. Additionally, plasma samples from toxicology studies confirmed that 8 did not form any reactive metabolites. However, 8 caused the identical microscopic skin lesions in NHPs found with 7, albeit with lower severity. Holistically, this work supports the hypothesis that this unique toxicity may be mechanism-based although additional work is required to confirm this and determine clinical relevance.
Collapse
Affiliation(s)
- Antonia F Stepan
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Michelle M Claffey
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Matthew R Reese
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Gayatri Balan
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Gabriela Barreiro
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Jason Barricklow
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Michael J Bohanon
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Brian P Boscoe
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Gregg D Cappon
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Lois K Chenard
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Julie Cianfrogna
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Laigao Chen
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Karen J Coffman
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Susan E Drozda
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Joshua R Dunetz
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Somraj Ghosh
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Xinjun Hou
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Christopher Houle
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Kapil Karki
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - John T Lazzaro
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Jessica Y Mancuso
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - John M Marcek
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Emily L Miller
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Mark A Moen
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Steven O'Neil
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Isao Sakurada
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Marc Skaddan
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Vinod Parikh
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Deborah L Smith
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Patrick Trapa
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Jamison B Tuttle
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Patrick R Verhoest
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Daniel P Walker
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Annie Won
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Ann S Wright
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Jessica Whritenour
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Kenneth Zasadny
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Margaret M Zaleska
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Lei Zhang
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| | - Christopher L Shaffer
- Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States.,Pharmaceutical Sciences, ⊥Pharmacokinetics, Dynamics, and Metabolism, #Biostatistics, Early Clinical Development, ∇Drug Safety Research and Development, and ○BioImaging Center, Pfizer Inc. , Groton, Connecticut 06340, United States
| |
Collapse
|
9
|
Helal CJ, Arnold EP, Boyden TL, Chang C, Chappie TA, Fennell KF, Forman MD, Hajos M, Harms JF, Hoffman WE, Humphrey JM, Kang Z, Kleiman RJ, Kormos BL, Lee CW, Lu J, Maklad N, McDowell L, Mente S, O’Connor RE, Pandit J, Piotrowski M, Schmidt AW, Schmidt CJ, Ueno H, Verhoest PR, Yang EX. Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor. J Med Chem 2017; 60:5673-5698. [DOI: 10.1021/acs.jmedchem.7b00397] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Affiliation(s)
- Christopher J. Helal
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Eric P. Arnold
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Tracey L. Boyden
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Cheng Chang
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Thomas A. Chappie
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Kimberly F. Fennell
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Michael D. Forman
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Mihaly Hajos
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - John F. Harms
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - William E. Hoffman
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - John M. Humphrey
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Zhijun Kang
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Robin J. Kleiman
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Bethany L. Kormos
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Che-Wah Lee
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jiemin Lu
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Noha Maklad
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Laura McDowell
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Scot Mente
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Rebecca E. O’Connor
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jayvardhan Pandit
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Mary Piotrowski
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Anne W. Schmidt
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Christopher J. Schmidt
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Hirokazu Ueno
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Patrick R. Verhoest
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Edward X. Yang
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
10
|
Pettersson M, Johnson DS, Rankic DA, Kauffman GW, Am Ende CW, Butler TW, Boscoe B, Evrard E, Helal CJ, Humphrey JM, Stepan AF, Stiff CM, Yang E, Xie L, Bales KR, Hajos-Korcsok E, Jenkinson S, Pettersen B, Pustilnik LR, Ramirez DS, Steyn SJ, Wood KM, Verhoest PR. Discovery of cyclopropyl chromane-derived pyridopyrazine-1,6-dione γ-secretase modulators with robust central efficacy. Medchemcomm 2017; 8:730-743. [PMID: 30108792 PMCID: PMC6071960 DOI: 10.1039/c6md00406g] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/18/2016] [Accepted: 10/05/2016] [Indexed: 11/21/2022]
Abstract
Herein we describe the discovery of a novel series of cyclopropyl chromane-derived pyridopyrazine-1,6-dione γ-secretase modulators for the treatment of Alzheimer's disease (AD). Using ligand-based design tactics such as conformational analysis and molecular modeling, a cyclopropyl chromane unit was identified as a suitable heterocyclic replacement for a naphthyl moiety that was present in the preliminary lead 4. The optimized lead molecule 44 achieved good central exposure resulting in robust and sustained reduction of brain amyloid-β42 (Aβ42) when dosed orally at 10 mg kg-1 in a rat time-course study. Application of the unpaced isolated heart Langendorff model enabled efficient differentiation of compounds with respect to cardiovascular safety, highlighting how minor structural changes can greatly impact the safety profile within a series of compounds.
Collapse
Affiliation(s)
- Martin Pettersson
- Neuroscience and Pain Medicinal Chemistry , Cambridge , Massachusetts 02139 , USA . ; Tel: +(617) 395 0705
| | - Douglas S Johnson
- Neuroscience and Pain Medicinal Chemistry , Cambridge , Massachusetts 02139 , USA . ; Tel: +(617) 395 0705
| | - Danica A Rankic
- Neuroscience and Pain Medicinal Chemistry , Groton , Connecticut 06340 , USA . ; Tel: +(860) 441 4354
| | - Gregory W Kauffman
- Neuroscience and Pain Medicinal Chemistry , Cambridge , Massachusetts 02139 , USA . ; Tel: +(617) 395 0705
| | - Christopher W Am Ende
- Neuroscience and Pain Medicinal Chemistry , Groton , Connecticut 06340 , USA . ; Tel: +(860) 441 4354
| | - Todd W Butler
- Neuroscience and Pain Medicinal Chemistry , Groton , Connecticut 06340 , USA . ; Tel: +(860) 441 4354
| | - Brian Boscoe
- Neuroscience and Pain Medicinal Chemistry , Groton , Connecticut 06340 , USA . ; Tel: +(860) 441 4354
| | - Edelweiss Evrard
- Neuroscience and Pain Medicinal Chemistry , Cambridge , Massachusetts 02139 , USA . ; Tel: +(617) 395 0705
| | - Christopher J Helal
- Neuroscience and Pain Medicinal Chemistry , Groton , Connecticut 06340 , USA . ; Tel: +(860) 441 4354
| | - John M Humphrey
- Neuroscience and Pain Medicinal Chemistry , Groton , Connecticut 06340 , USA . ; Tel: +(860) 441 4354
| | - Antonia F Stepan
- Neuroscience and Pain Medicinal Chemistry , Cambridge , Massachusetts 02139 , USA . ; Tel: +(617) 395 0705
| | - Cory M Stiff
- Neuroscience and Pain Medicinal Chemistry , Groton , Connecticut 06340 , USA . ; Tel: +(860) 441 4354
| | - Eddie Yang
- Neuroscience and Pain Medicinal Chemistry , Groton , Connecticut 06340 , USA . ; Tel: +(860) 441 4354
| | - Longfei Xie
- Neuroscience and Pain Medicinal Chemistry , Groton , Connecticut 06340 , USA . ; Tel: +(860) 441 4354
| | - Kelly R Bales
- Neuroscience and Pain Research Unit , Cambridge , Massachusetts 02139 , USA
| | - Eva Hajos-Korcsok
- Neuroscience and Pain Research Unit , Cambridge , Massachusetts 02139 , USA
| | - Stephen Jenkinson
- Global Safety Pharmacology , Pfizer Worldwide Research and Development , La Jolla , California 92121 , USA
| | - Betty Pettersen
- Drug Safety R&D , Pfizer Worldwide Research and Development , Groton , Connecticut 06340 , USA
| | | | - David S Ramirez
- Global Safety Pharmacology , Pfizer Worldwide Research and Development , La Jolla , California 92121 , USA
| | - Stefanus J Steyn
- Pharmacokinetics, Dynamics and Metabolism , Pfizer Worldwide Research and Development , Cambridge , Massachusetts 02139 , USA
| | - Kathleen M Wood
- Neuroscience and Pain Research Unit , Cambridge , Massachusetts 02139 , USA
| | - Patrick R Verhoest
- Neuroscience and Pain Medicinal Chemistry , Cambridge , Massachusetts 02139 , USA . ; Tel: +(617) 395 0705
| |
Collapse
|
11
|
Abstract
Significant progress has been made in prospectively designing molecules using the central nervous system multiparameter optimization (CNS MPO) desirability tool, as evidenced by the analysis reported herein of a second wave of drug candidates that originated after the development and implementation of this tool. This simple-to-use design algorithm has expanded design space for CNS candidates and has further demonstrated the advantages of utilizing a flexible, multiparameter approach in drug discovery rather than individual parameters and hard cutoffs of physicochemical properties. The CNS MPO tool has helped to increase the percentage of compounds nominated for clinical development that exhibit alignment of ADME attributes, cross the blood-brain barrier, and reside in lower-risk safety space (low ClogP and high TPSA). The use of this tool has played a role in reducing the number of compounds submitted to exploratory toxicity studies and increasing the survival of our drug candidates through regulatory toxicology into First in Human studies. Overall, the CNS MPO algorithm has helped to improve the prioritization of design ideas and the quality of the compounds nominated for clinical development.
Collapse
Affiliation(s)
- Travis T. Wager
- Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Xinjun Hou
- Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Patrick R. Verhoest
- Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Anabella Villalobos
- Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
12
|
Pettersson M, Hou X, Kuhn M, Wager TT, Kauffman GW, Verhoest PR. Quantitative Assessment of the Impact of Fluorine Substitution on P-Glycoprotein (P-gp) Mediated Efflux, Permeability, Lipophilicity, and Metabolic Stability. J Med Chem 2016; 59:5284-96. [DOI: 10.1021/acs.jmedchem.6b00027] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Martin Pettersson
- Worldwide
Medicinal Chemistry, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Xinjun Hou
- Worldwide
Medicinal Chemistry, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Max Kuhn
- Research
Statistics, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Travis T. Wager
- Worldwide
Medicinal Chemistry, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Gregory W. Kauffman
- Computational
ADME Group, Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Patrick R. Verhoest
- Worldwide
Medicinal Chemistry, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
13
|
Wang Q, Amato SP, Rubitski DM, Hayward MM, Kormos BL, Verhoest PR, Xu L, Brandon NJ, Ehlers MD. Identification of Phosphorylation Consensus Sequences and Endogenous Neuronal Substrates of the Psychiatric Risk Kinase TNIK. J Pharmacol Exp Ther 2015; 356:410-23. [PMID: 26645429 DOI: 10.1124/jpet.115.229880] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2015] [Accepted: 12/01/2015] [Indexed: 12/28/2022] Open
Abstract
Traf2- and Nck-interacting kinase (TNIK) is a serine/threonine kinase highly expressed in the brain and enriched in the postsynaptic density of glutamatergic synapses in the mammalian brain. Accumulating genetic evidence and functional data have implicated TNIK as a risk factor for psychiatric disorders. However, the endogenous substrates of TNIK in neurons are unknown. Here, we describe a novel selective small molecule inhibitor of the TNIK kinase family. Using this inhibitor, we report the identification of endogenous neuronal TNIK substrates by immunoprecipitation with a phosphomotif antibody followed by mass spectrometry. Phosphorylation consensus sequences were defined by phosphopeptide sequence analysis. Among the identified substrates were members of the delta-catenin family including p120-catenin, δ-catenin, and armadillo repeat gene deleted in velo-cardio-facial syndrome (ARVCF), each of which is linked to psychiatric or neurologic disorders. Using p120-catenin as a representative substrate, we show TNIK-induced p120-catenin phosphorylation in cells requires intact kinase activity and phosphorylation of TNIK at T181 and T187 in the activation loop. Addition of the small molecule TNIK inhibitor or knocking down TNIK by two shRNAs reduced endogenous p120-catenin phosphorylation in cells. Together, using a TNIK inhibitor and phosphomotif antibody, we identify endogenous substrates of TNIK in neurons, define consensus sequences for TNIK, and suggest signaling pathways by which TNIK influences synaptic development and function linked to psychiatric and neurologic disorders.
Collapse
Affiliation(s)
- Qi Wang
- Neuroscience & Pain Research Unit, BioTherapeutics Research and Development, Pfizer Inc. Cambridge, Massachusetts (Q.W., S.P.A., D.M.R., N.J.B., M.D.E.); Center of Chemistry Innovation and Excellence, Pfizer Inc., Groton, Connecticut (M.M.H.); Neuroscience Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts (B.L.K., P.R.V.);and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts (L.X.)
| | - Stephen P Amato
- Neuroscience & Pain Research Unit, BioTherapeutics Research and Development, Pfizer Inc. Cambridge, Massachusetts (Q.W., S.P.A., D.M.R., N.J.B., M.D.E.); Center of Chemistry Innovation and Excellence, Pfizer Inc., Groton, Connecticut (M.M.H.); Neuroscience Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts (B.L.K., P.R.V.);and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts (L.X.)
| | - David M Rubitski
- Neuroscience & Pain Research Unit, BioTherapeutics Research and Development, Pfizer Inc. Cambridge, Massachusetts (Q.W., S.P.A., D.M.R., N.J.B., M.D.E.); Center of Chemistry Innovation and Excellence, Pfizer Inc., Groton, Connecticut (M.M.H.); Neuroscience Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts (B.L.K., P.R.V.);and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts (L.X.)
| | - Matthew M Hayward
- Neuroscience & Pain Research Unit, BioTherapeutics Research and Development, Pfizer Inc. Cambridge, Massachusetts (Q.W., S.P.A., D.M.R., N.J.B., M.D.E.); Center of Chemistry Innovation and Excellence, Pfizer Inc., Groton, Connecticut (M.M.H.); Neuroscience Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts (B.L.K., P.R.V.);and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts (L.X.)
| | - Bethany L Kormos
- Neuroscience & Pain Research Unit, BioTherapeutics Research and Development, Pfizer Inc. Cambridge, Massachusetts (Q.W., S.P.A., D.M.R., N.J.B., M.D.E.); Center of Chemistry Innovation and Excellence, Pfizer Inc., Groton, Connecticut (M.M.H.); Neuroscience Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts (B.L.K., P.R.V.);and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts (L.X.)
| | - Patrick R Verhoest
- Neuroscience & Pain Research Unit, BioTherapeutics Research and Development, Pfizer Inc. Cambridge, Massachusetts (Q.W., S.P.A., D.M.R., N.J.B., M.D.E.); Center of Chemistry Innovation and Excellence, Pfizer Inc., Groton, Connecticut (M.M.H.); Neuroscience Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts (B.L.K., P.R.V.);and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts (L.X.)
| | - Lan Xu
- Neuroscience & Pain Research Unit, BioTherapeutics Research and Development, Pfizer Inc. Cambridge, Massachusetts (Q.W., S.P.A., D.M.R., N.J.B., M.D.E.); Center of Chemistry Innovation and Excellence, Pfizer Inc., Groton, Connecticut (M.M.H.); Neuroscience Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts (B.L.K., P.R.V.);and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts (L.X.)
| | - Nicholas J Brandon
- Neuroscience & Pain Research Unit, BioTherapeutics Research and Development, Pfizer Inc. Cambridge, Massachusetts (Q.W., S.P.A., D.M.R., N.J.B., M.D.E.); Center of Chemistry Innovation and Excellence, Pfizer Inc., Groton, Connecticut (M.M.H.); Neuroscience Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts (B.L.K., P.R.V.);and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts (L.X.)
| | - Michael D Ehlers
- Neuroscience & Pain Research Unit, BioTherapeutics Research and Development, Pfizer Inc. Cambridge, Massachusetts (Q.W., S.P.A., D.M.R., N.J.B., M.D.E.); Center of Chemistry Innovation and Excellence, Pfizer Inc., Groton, Connecticut (M.M.H.); Neuroscience Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts (B.L.K., P.R.V.);and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts (L.X.)
| |
Collapse
|
14
|
Affiliation(s)
- Amy B. Dounay
- Department
of Chemistry and Biochemistry, Colorado College, 14 E. Cache
La Poudre Street, Colorado Springs, Colorado 80903, United States
| | - Jamison B. Tuttle
- Worldwide Medicinal Chemistry, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Patrick R. Verhoest
- Worldwide Medicinal Chemistry, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
15
|
Pettersson M, Johnson DS, Humphrey JM, Butler TW, am Ende CW, Fish BA, Green ME, Kauffman GW, Mullins PB, O’Donnell CJ, Stepan AF, Stiff CM, Subramanyam C, Tran TP, Vetelino BC, Yang E, Xie L, Bales KR, Pustilnik LR, Steyn SJ, Wood KM, Verhoest PR. Design of Pyridopyrazine-1,6-dione γ-Secretase Modulators that Align Potency, MDR Efflux Ratio, and Metabolic Stability. ACS Med Chem Lett 2015; 6:596-601. [PMID: 26005540 DOI: 10.1021/acsmedchemlett.5b00070] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2015] [Accepted: 03/27/2015] [Indexed: 12/16/2022] Open
Abstract
Herein we describe the design and synthesis of a series of pyridopyrazine-1,6-dione γ-secretase modulators (GSMs) for Alzheimer's disease (AD) that achieve good alignment of potency, metabolic stability, and low MDR efflux ratios, while also maintaining favorable physicochemical properties. Specifically, incorporation of fluorine enabled design of metabolically less liable lipophilic alkyl substituents to increase potency without compromising the sp(3)-character. The lead compound 21 (PF-06442609) displayed a favorable rodent pharmacokinetic profile, and robust reductions of brain Aβ42 and Aβ40 were observed in a guinea pig time-course experiment.
Collapse
Affiliation(s)
- Martin Pettersson
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Douglas S. Johnson
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - John M. Humphrey
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Todd W. Butler
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Christopher W. am Ende
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Benjamin A. Fish
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Michael E. Green
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Gregory W. Kauffman
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Patrick B. Mullins
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Christopher J. O’Donnell
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Antonia F. Stepan
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Cory M. Stiff
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Chakrapani Subramanyam
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Tuan P. Tran
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Beth Cooper Vetelino
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Eddie Yang
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Longfei Xie
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Kelly R. Bales
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Leslie R. Pustilnik
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Stefanus J. Steyn
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Kathleen M. Wood
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Patrick R. Verhoest
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
16
|
Pettersson M, Johnson DS, Humphrey JM, am Ende CW, Evrard E, Efremov I, Kauffman GW, Stepan AF, Stiff CM, Xie L, Bales KR, Hajos-Korcsok E, Murrey HE, Pustilnik LR, Steyn SJ, Wood KM, Verhoest PR. Discovery of indole-derived pyridopyrazine-1,6-dione γ-secretase modulators that target presenilin. Bioorg Med Chem Lett 2015; 25:908-13. [DOI: 10.1016/j.bmcl.2014.12.059] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2014] [Revised: 12/13/2014] [Accepted: 12/16/2014] [Indexed: 01/29/2023]
|
17
|
Schülke JP, McAllister LA, Geoghegan KF, Parikh V, Chappie TA, Verhoest PR, Schmidt CJ, Johnson DS, Brandon NJ. Chemoproteomics demonstrates target engagement and exquisite selectivity of the clinical phosphodiesterase 10A inhibitor MP-10 in its native environment. ACS Chem Biol 2014; 9:2823-32. [PMID: 25295858 DOI: 10.1021/cb500671j] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Phosphodiesterases (PDEs) regulate the levels of the second messengers cAMP and cGMP and are important drug targets. PDE10A is highly enriched in medium spiny neurons of the striatum and is an attractive drug target for the treatment of basal ganglia diseases like schizophrenia, Parkinson's disease, or Huntington's disease. Here we describe the design, synthesis, and application of a variety of chemical biology probes, based on the first clinically tested PDE10A inhibitor MP-10, which were used to characterize the chemoproteomic profile of the clinical candidate in its native environment. A clickable photoaffinity probe was used to measure target engagement of MP-10 and revealed differences between whole cell and membrane preparations. Moreover, our results illustrate the importance of the linker design in the creation of functional probes. Biotinylated affinity probes allowed identification of drug-interaction partners in rodent and human tissue and quantitative mass spectrometry analysis revealed highly specific binding of MP-10 to PDE10A with virtually no off-target binding. The profiling of PDE10A chemical biology probes described herein illustrates a strategy by which high affinity inhibitors can be converted into probes for determining selectivity and target engagement of drug candidates in complex biological matrices from native sources.
Collapse
Affiliation(s)
- Jan-Philip Schülke
- Neuroscience
Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139 (United States)
| | - Laura A. McAllister
- Neuroscience
Medicinal Chemistry and Chemical Biology, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139 (United States)
| | - Kieran F. Geoghegan
- Center
of Chemistry, Pfizer Worldwide Research and Development, Groton, Connecticut 06340 (United States)
| | - Vinod Parikh
- Center
of Chemistry, Pfizer Worldwide Research and Development, Groton, Connecticut 06340 (United States)
| | - Thomas A. Chappie
- Neuroscience
Medicinal Chemistry and Chemical Biology, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139 (United States)
| | - Patrick R. Verhoest
- Neuroscience
Medicinal Chemistry and Chemical Biology, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139 (United States)
| | - Christopher J. Schmidt
- Neuroscience
Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139 (United States)
| | - Douglas S. Johnson
- Neuroscience
Medicinal Chemistry and Chemical Biology, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139 (United States)
| | - Nicholas J. Brandon
- Neuroscience
Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139 (United States)
| |
Collapse
|
18
|
Henderson JL, Kormos BL, Hayward MM, Coffman KJ, Jasti J, Kurumbail RG, Wager TT, Verhoest PR, Noell GS, Chen Y, Needle E, Berger Z, Steyn SJ, Houle C, Hirst WD, Galatsis P. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem 2014; 58:419-32. [PMID: 25353650 DOI: 10.1021/jm5014055] [Citation(s) in RCA: 122] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Leucine rich repeat kinase 2 (LRRK2) has been genetically linked to Parkinson's disease (PD) by genome-wide association studies (GWAS). The most common LRRK2 mutation, G2019S, which is relatively rare in the total population, gives rise to increased kinase activity. As such, LRRK2 kinase inhibitors are potentially useful in the treatment of PD. We herein disclose the discovery and optimization of a novel series of potent LRRK2 inhibitors, focusing on improving kinome selectivity using a surrogate crystallography approach. This resulted in the identification of 14 (PF-06447475), a highly potent, brain penetrant and selective LRRK2 inhibitor which has been further profiled in in vivo safety and pharmacodynamic studies.
Collapse
Affiliation(s)
- Jaclyn L Henderson
- Worldwide Medicinal Chemistry, ‡Neuroscience Research Unit, and §Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide R&D , 610 Main Street, Cambridge, Massachusetts 02139, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Galatsis P, Henderson JL, Kormos BL, Han S, Kurumbail RG, Wager TT, Verhoest PR, Noell GS, Chen Y, Needle E, Berger Z, Steyn SJ, Houle C, Hirst WD. Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold. Bioorg Med Chem Lett 2014; 24:4132-40. [DOI: 10.1016/j.bmcl.2014.07.052] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2014] [Accepted: 07/18/2014] [Indexed: 01/10/2023]
|
20
|
Chekler ELP, Unwalla R, Khan TA, Tangirala RS, Johnson M, St. Andre M, Anderson JT, Kenney T, Chiparri S, McNally C, Kilbourne E, Thompson C, Nagpal S, Weber G, Schelling S, Owens J, Morris CA, Powell D, Verhoest PR, Gilbert AM. 1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile Derivatives as Potent and Tissue Selective Androgen Receptor Modulators. J Med Chem 2014; 57:2462-71. [DOI: 10.1021/jm401625b] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Eugene L. Piatnitski Chekler
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Rayomond Unwalla
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Taukeer A. Khan
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Raghuram S. Tangirala
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Mark Johnson
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Michael St. Andre
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - James T. Anderson
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Thomas Kenney
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Sue Chiparri
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Chris McNally
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Edward Kilbourne
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Catherine Thompson
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Sunil Nagpal
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Gregory Weber
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Scott Schelling
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Jane Owens
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Carl A. Morris
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Dennis Powell
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Patrick R. Verhoest
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Adam M. Gilbert
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| |
Collapse
|
21
|
Pettersson M, Johnson DS, Subramanyam C, Bales KR, am Ende CW, Fish BA, Green ME, Kauffman GW, Mullins PB, Navaratnam T, Sakya SM, Stiff CM, Tran TP, Xie L, Zhang L, Pustilnik LR, Vetelino BC, Wood KM, Pozdnyakov N, Verhoest PR, O’Donnell CJ. Design, Synthesis, and Pharmacological Evaluation of a Novel Series of Pyridopyrazine-1,6-dione γ-Secretase Modulators. J Med Chem 2014; 57:1046-62. [DOI: 10.1021/jm401782h] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Martin Pettersson
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Douglas S. Johnson
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Chakrapani Subramanyam
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Kelly R. Bales
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Christopher W. am Ende
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Benjamin A. Fish
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Michael E. Green
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Gregory W. Kauffman
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Patrick B. Mullins
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Thayalan Navaratnam
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Subas M. Sakya
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Cory M. Stiff
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Tuan P. Tran
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Longfei Xie
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Liming Zhang
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Leslie R. Pustilnik
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Beth C. Vetelino
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Kathleen M. Wood
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Nikolay Pozdnyakov
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Patrick R. Verhoest
- Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Christopher J. O’Donnell
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
22
|
Zhang L, Balan G, Barreiro G, Boscoe BP, Chenard LK, Cianfrogna J, Claffey MM, Chen L, Coffman KJ, Drozda SE, Dunetz JR, Fonseca KR, Galatsis P, Grimwood S, Lazzaro JT, Mancuso JY, Miller EL, Reese MR, Rogers BN, Sakurada I, Skaddan M, Smith DL, Stepan AF, Trapa P, Tuttle JB, Verhoest PR, Walker DP, Wright AS, Zaleska MM, Zasadny K, Shaffer CL. Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator. J Med Chem 2014; 57:861-77. [PMID: 24392688 DOI: 10.1021/jm401622k] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A novel series of pyrazolopyrazines is herein disclosed as mGluR5 negative allosteric modulators (NAMs). Starting from a high-throughput screen (HTS) hit (1), a systematic structure-activity relationship (SAR) study was conducted with a specific focus on balancing pharmacological potency with physicochemical and pharmacokinetic (PK) properties. This effort led to the discovery of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo[3,4-b]pyrazine (PF470, 14) as a highly potent, selective, and orally bioavailable mGluR5 NAM. Compound 14 demonstrated robust efficacy in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-rendered Parkinsonian nonhuman primate model of l-DOPA-induced dyskinesia (PD-LID). However, the progression of 14 to the clinic was terminated because of a potentially mechanism-mediated finding consistent with a delayed-type immune-mediated type IV hypersensitivity in a 90-day NHP regulatory toxicology study.
Collapse
Affiliation(s)
- Lei Zhang
- Neuroscience Medicinal Chemistry, ‡Neuroscience Pharmacokinetics, Dynamics and Metabolism, and §Neuroscience Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Stepan AF, Kauffman GW, Keefer CE, Verhoest PR, Edwards M. Evaluating the Differences in Cycloalkyl Ether Metabolism Using the Design Parameter “Lipophilic Metabolism Efficiency” (LipMetE) and a Matched Molecular Pairs Analysis. J Med Chem 2013; 56:6985-90. [DOI: 10.1021/jm4008642] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Affiliation(s)
- Antonia F. Stepan
- Pfizer Worldwide Research & Development, 700 Main Street, Cambridge, Massachusetts 02139, United States
| | - Gregory W. Kauffman
- Pfizer Worldwide Research & Development, 700 Main Street, Cambridge, Massachusetts 02139, United States
| | - Christopher E. Keefer
- Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Patrick R. Verhoest
- Pfizer Worldwide Research & Development, 700 Main Street, Cambridge, Massachusetts 02139, United States
| | - Martin Edwards
- Pfizer Worldwide Research & Development, 10770 Science Center Drive, La Jolla, California 92121, United States
| |
Collapse
|
24
|
Zhang L, Villalobos A, Beck EM, Bocan T, Chappie TA, Chen L, Grimwood S, Heck SD, Helal CJ, Hou X, Humphrey JM, Lu J, Skaddan MB, McCarthy TJ, Verhoest PR, Wager TT, Zasadny K. Design and Selection Parameters to Accelerate the Discovery of Novel Central Nervous System Positron Emission Tomography (PET) Ligands and Their Application in the Development of a Novel Phosphodiesterase 2A PET Ligand. J Med Chem 2013; 56:4568-79. [DOI: 10.1021/jm400312y] [Citation(s) in RCA: 141] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Lei Zhang
- Neuroscience Medicinal Chemistry,
Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Anabella Villalobos
- Neuroscience Medicinal Chemistry,
Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Elizabeth M. Beck
- Neuroscience Medicinal Chemistry,
Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Thomas Bocan
- BioImaging Center, Precision Medicine,
Pfizer Inc., Groton, Connecticut 06340, United States
| | - Thomas A. Chappie
- Neuroscience Medicinal Chemistry,
Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Laigao Chen
- BioImaging Center, Precision Medicine,
Pfizer Inc., Groton, Connecticut 06340, United States
| | - Sarah Grimwood
- Neuroscience Research Unit,
Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Steven D. Heck
- Data Analytical Group, Groton
Center of Chemistry, Groton, Connecticut 06340, United States
| | - Christopher J. Helal
- Neuroscience Medicinal Chemistry,
Pfizer Inc., Groton, Connecticut 06340, United States
| | - Xinjun Hou
- Neuroscience Medicinal Chemistry,
Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - John M. Humphrey
- Neuroscience Medicinal Chemistry,
Pfizer Inc., Groton, Connecticut 06340, United States
| | - Jiemin Lu
- Neuroscience Medicinal Chemistry,
Pfizer Inc., Groton, Connecticut 06340, United States
| | - Marc B. Skaddan
- BioImaging Center, Precision Medicine,
Pfizer Inc., Groton, Connecticut 06340, United States
| | - Timothy J. McCarthy
- BioImaging Center, Precision Medicine,
Pfizer Inc., Groton, Connecticut 06340, United States
| | - Patrick R. Verhoest
- Neuroscience Medicinal Chemistry,
Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Travis T. Wager
- Neuroscience Medicinal Chemistry,
Pfizer Inc., Cambridge, Massachusetts 02139, United States
| | - Kenneth Zasadny
- BioImaging Center, Precision Medicine,
Pfizer Inc., Groton, Connecticut 06340, United States
| |
Collapse
|
25
|
Tuttle JB, Anderson M, Bechle BM, Campbell BM, Chang C, Dounay AB, Evrard E, Fonseca KR, Gan X, Ghosh S, Horner W, James LC, Kim JY, McAllister LA, Pandit J, Parikh VD, Rago BJ, Salafia MA, Strick CA, Zawadzke LE, Verhoest PR. Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing Interactions. ACS Med Chem Lett 2013; 4:37-40. [PMID: 24900560 DOI: 10.1021/ml300237v] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2012] [Accepted: 10/24/2012] [Indexed: 11/29/2022] Open
Abstract
A series of aryl hydroxamates recently have been disclosed as irreversible inhibitors of kynurenine amino transferase II (KAT II), an enzyme that may play a role in schizophrenia and other psychiatric and neurological disorders. The utilization of structure-activity relationships (SAR) in conjunction with X-ray crystallography led to the discovery of hydroxamate 4, a disubstituted analogue that has a significant potency enhancement due to a novel interaction with KAT II. The use of k inact/K i to assess potency was critical for understanding the SAR in this series and for identifying compounds with improved pharmacodynamic profiles.
Collapse
Affiliation(s)
- Jamison B. Tuttle
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Marie Anderson
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Bruce M. Bechle
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Brian M. Campbell
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Cheng Chang
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Amy B. Dounay
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Edelweiss Evrard
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Kari R. Fonseca
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Xinmin Gan
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Somraj Ghosh
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Weldon Horner
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Larry C. James
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Ji-Young Kim
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Laura A. McAllister
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Jayvardhan Pandit
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Vinod D. Parikh
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Brian J. Rago
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Michelle A. Salafia
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Christine A. Strick
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Laura E. Zawadzke
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Patrick R. Verhoest
- Pfizer Worldwide Research and Development, Neuroscience Medicinal Chemistry, Eastern
Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
26
|
Henderson JL, Sawant-Basak A, Tuttle JB, Dounay AB, McAllister LA, Pandit J, Rong S, Hou X, Bechle BM, Kim JY, Parikh V, Ghosh S, Evrard E, Zawadzke LE, Salafia MA, Rago B, Obach RS, Clark A, Fonseca KR, Chang C, Verhoest PR. Discovery of hydroxamate bioisosteres as KAT II inhibitors with improved oral bioavailability and pharmacokinetics. Med Chem Commun 2013. [DOI: 10.1039/c2md20166f] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A series of kynurenine aminotransferase II (KAT II) inhibitors has been developed replacing the hydroxamate motif with a bioisostere.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Suobao Rong
- Neuroscience Medicinal Chemistry
- Cambridge
- USA
| | - Xinjun Hou
- Neuroscience Medicinal Chemistry
- Cambridge
- USA
| | | | | | | | | | | | | | | | - Brian Rago
- Neuroscience Medicinal Chemistry
- Cambridge
- USA
| | | | - Alan Clark
- Neuroscience Medicinal Chemistry
- Cambridge
- USA
| | | | - Cheng Chang
- Neuroscience Medicinal Chemistry
- Cambridge
- USA
| | | |
Collapse
|
27
|
Claffey MM, Helal CJ, Verhoest PR, Kang Z, Fors KS, Jung S, Zhong J, Bundesmann MW, Hou X, Lui S, Kleiman RJ, Vanase-Frawley M, Schmidt AW, Menniti F, Schmidt CJ, Hoffman WE, Hajos M, McDowell L, O'Connor RE, Macdougall-Murphy M, Fonseca KR, Becker SL, Nelson FR, Liras S. Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors. J Med Chem 2012; 55:9055-68. [PMID: 23025719 DOI: 10.1021/jm3009635] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Phosphodiesterase 9A inhibitors have shown activity in preclinical models of cognition with potential application as novel therapies for treating Alzheimer's disease. Our clinical candidate, PF-04447943 (2), demonstrated acceptable CNS permeability in rats with modest asymmetry between central and peripheral compartments (free brain/free plasma = 0.32; CSF/free plasma = 0.19) yet had physicochemical properties outside the range associated with traditional CNS drugs. To address the potential risk of restricted CNS penetration with 2 in human clinical trials, we sought to identify a preclinical candidate with no asymmetry in rat brain penetration and that could advance into development. Merging the medicinal chemistry strategies of structure-based design with parallel chemistry, a novel series of PDE9A inhibitors was identified that showed improved selectivity over PDE1C. Optimization afforded preclinical candidate 19 that demonstrated free brain/free plasma ≥ 1 in rat and reduced microsomal clearance along with the ability to increase cyclic guanosine monophosphosphate levels in rat CSF.
Collapse
Affiliation(s)
- Michelle M Claffey
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Verhoest PR, Fonseca KR, Hou X, Proulx-LaFrance C, Corman M, Helal CJ, Claffey MM, Tuttle JB, Coffman KJ, Liu S, Nelson F, Kleiman RJ, Menniti FS, Schmidt CJ, Vanase-Frawley M, Liras S. Design and Discovery of 6-[(3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a Selective Brain Penetrant PDE9A Inhibitor for the Treatment of Cognitive Disorders. J Med Chem 2012; 55:9045-54. [DOI: 10.1021/jm3007799] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Patrick R. Verhoest
- Neuroscience
Medicinal Chemistry, Pfizer World Wide Research and Development, 700 Main Street,
Cambridge, Massachusetts 02139, United States
| | - Kari R. Fonseca
- Neuroscience
Medicinal Chemistry, Pfizer World Wide Research and Development, 700 Main Street,
Cambridge, Massachusetts 02139, United States
| | - Xinjun Hou
- Neuroscience
Medicinal Chemistry, Pfizer World Wide Research and Development, 700 Main Street,
Cambridge, Massachusetts 02139, United States
| | - Caroline Proulx-LaFrance
- Neuroscience
Medicinal Chemistry, Pfizer World Wide Research and Development, 700 Main Street,
Cambridge, Massachusetts 02139, United States
| | - Michael Corman
- Neuroscience
Medicinal Chemistry, Pfizer World Wide Research and Development, 700 Main Street,
Cambridge, Massachusetts 02139, United States
| | - Christopher J. Helal
- Neuroscience
Medicinal Chemistry, Pfizer World Wide Research and Development, 700 Main Street,
Cambridge, Massachusetts 02139, United States
| | - Michelle M. Claffey
- Neuroscience
Medicinal Chemistry, Pfizer World Wide Research and Development, 700 Main Street,
Cambridge, Massachusetts 02139, United States
| | - Jamison B. Tuttle
- Neuroscience
Medicinal Chemistry, Pfizer World Wide Research and Development, 700 Main Street,
Cambridge, Massachusetts 02139, United States
| | - Karen J. Coffman
- Neuroscience
Medicinal Chemistry, Pfizer World Wide Research and Development, 700 Main Street,
Cambridge, Massachusetts 02139, United States
| | - Shenpinq Liu
- Neuroscience
Medicinal Chemistry, Pfizer World Wide Research and Development, 700 Main Street,
Cambridge, Massachusetts 02139, United States
| | - Frederick Nelson
- Neuroscience
Medicinal Chemistry, Pfizer World Wide Research and Development, 700 Main Street,
Cambridge, Massachusetts 02139, United States
| | - Robin J. Kleiman
- Neuroscience
Medicinal Chemistry, Pfizer World Wide Research and Development, 700 Main Street,
Cambridge, Massachusetts 02139, United States
| | - Frank S. Menniti
- Neuroscience
Medicinal Chemistry, Pfizer World Wide Research and Development, 700 Main Street,
Cambridge, Massachusetts 02139, United States
| | - Christopher J. Schmidt
- Neuroscience
Medicinal Chemistry, Pfizer World Wide Research and Development, 700 Main Street,
Cambridge, Massachusetts 02139, United States
| | - Michelle Vanase-Frawley
- Neuroscience
Medicinal Chemistry, Pfizer World Wide Research and Development, 700 Main Street,
Cambridge, Massachusetts 02139, United States
| | - Spiros Liras
- Neuroscience
Medicinal Chemistry, Pfizer World Wide Research and Development, 700 Main Street,
Cambridge, Massachusetts 02139, United States
| |
Collapse
|
29
|
Dounay AB, Anderson M, Bechle BM, Campbell BM, Claffey MM, Evdokimov A, Evrard E, Fonseca KR, Gan X, Ghosh S, Hayward MM, Horner W, Kim JY, McAllister LA, Pandit J, Paradis V, Parikh VD, Reese MR, Rong S, Salafia MA, Schuyten K, Strick CA, Tuttle JB, Valentine J, Wang H, Zawadzke LE, Verhoest PR. Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia. ACS Med Chem Lett 2012; 3:187-92. [PMID: 24900455 DOI: 10.1021/ml200204m] [Citation(s) in RCA: 69] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2011] [Accepted: 01/16/2012] [Indexed: 12/27/2022] Open
Abstract
Kynurenine aminotransferase (KAT) II has been identified as a potential new target for the treatment of cognitive impairment associated with schizophrenia and other psychiatric disorders. Following a high-throughput screen, cyclic hydroxamic acid PF-04859989 was identified as a potent and selective inhibitor of human and rat KAT II. An X-ray crystal structure and (13)C NMR studies of PF-04859989 bound to KAT II have demonstrated that this compound forms a covalent adduct with the enzyme cofactor, pyridoxal phosphate (PLP), in the active site. In vivo pharmacokinetic and efficacy studies in rat show that PF-04859989 is a brain-penetrant, irreversible inhibitor and is capable of reducing brain kynurenic acid by 50% at a dose of 10 mg/kg (sc). Preliminary structure-activity relationship investigations have been completed and have identified the positions on this scaffold best suited to modification for further optimization of this novel series of KAT II inhibitors.
Collapse
Affiliation(s)
- Amy B. Dounay
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Marie Anderson
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Bruce M. Bechle
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Brian M. Campbell
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Michelle M. Claffey
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Artem Evdokimov
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Edelweiss Evrard
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Kari R. Fonseca
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Xinmin Gan
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Somraj Ghosh
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Matthew M. Hayward
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Weldon Horner
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Ji-Young Kim
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Laura A. McAllister
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Jayvardhan Pandit
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Vanessa Paradis
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Vinod D. Parikh
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Matthew R. Reese
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - SuoBao Rong
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Michelle A. Salafia
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Katherine Schuyten
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Christine A. Strick
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Jamison B. Tuttle
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - James Valentine
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Hong Wang
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Laura E. Zawadzke
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| | - Patrick R. Verhoest
- Pfizer Worldwide Research and Development, Neuroscience Chemistry, Eastern Point Road,
Groton, Connecticut 06340, United States
| |
Collapse
|
30
|
Kleiman RJ, Chapin DS, Christoffersen C, Freeman J, Fonseca KR, Geoghegan KF, Grimwood S, Guanowsky V, Hajós M, Harms JF, Helal CJ, Hoffmann WE, Kocan GP, Majchrzak MJ, McGinnis D, McLean S, Menniti FS, Nelson F, Roof R, Schmidt AW, Seymour PA, Stephenson DT, Tingley FD, Vanase-Frawley M, Verhoest PR, Schmidt CJ. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo. J Pharmacol Exp Ther 2012; 341:396-409. [PMID: 22328573 DOI: 10.1124/jpet.111.191353] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Cyclic nucleotides are critical regulators of synaptic plasticity and participate in requisite signaling cascades implicated across multiple neurotransmitter systems. Phosphodiesterase 9A (PDE9A) is a high-affinity, cGMP-specific enzyme widely expressed in the rodent central nervous system. In the current study, we observed neuronal staining with antibodies raised against PDE9A protein in human cortex, cerebellum, and subiculum. We have also developed several potent, selective, and brain-penetrant PDE9A inhibitors and used them to probe the function of PDE9A in vivo. Administration of these compounds to animals led to dose-dependent accumulation of cGMP in brain tissue and cerebrospinal fluid, producing a range of biological effects that implied functional significance for PDE9A-regulated cGMP in dopaminergic, cholinergic, and serotonergic neurotransmission and were consistent with the widespread distribution of PDE9A. In vivo effects of PDE9A inhibition included reversal of the respective disruptions of working memory by ketamine, episodic and spatial memory by scopolamine, and auditory gating by amphetamine, as well as potentiation of risperidone-induced improvements in sensorimotor gating and reversal of the stereotypic scratching response to the hallucinogenic 5-hydroxytryptamine 2A agonist mescaline. The results suggested a role for PDE9A in the regulation of monoaminergic circuitry associated with sensory processing and memory. Thus, PDE9A activity regulates neuronal cGMP signaling downstream of multiple neurotransmitter systems, and inhibition of PDE9A may provide therapeutic benefits in psychiatric and neurodegenerative diseases promoted by the dysfunction of these diverse neurotransmitter systems.
Collapse
Affiliation(s)
- Robin J Kleiman
- SystaMedic Inc., 1084 Shennecossett Drive, Groton, CT 06340, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Piatnitski Chekler EL, Khan TA, Mamidala R, Anderson JT, Tangirala RS, Verhoest PR, Gilbert AM. Azaindolines: derisking the indoline structural alert. Tetrahedron Lett 2012. [DOI: 10.1016/j.tetlet.2011.11.070] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
32
|
Grimwood S, Lu Y, Schmidt AW, Vanase-Frawley MA, Sawant-Basak A, Miller E, McLean S, Freeman J, Wong S, McLaughlin JP, Verhoest PR. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors. J Pharmacol Exp Ther 2011; 339:555-66. [PMID: 21821697 DOI: 10.1124/jpet.111.185108] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
2-Methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242) is a novel κ-opioid receptor (KOR) antagonist with high affinity for human (3 nM), rat (21 nM), and mouse (22 nM) KOR, a ∼ 20-fold reduced affinity for human μ-opioid receptors (MORs; K(i) = 64 nM), and negligible affinity for δ-opioid receptors (K(i) > 4 μM). PF-04455242 also showed selectivity for KORs in vivo. In rats, PF-04455242 blocked KOR and MOR agonist-induced analgesia with ID(50) values of 1.5 and 9.8 mg/kg, respectively, and inhibited ex vivo [(3)H](2-(benzofuran-4-yl)-N-methyl-N-((5S,7R,8R)-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]decan-8-yl)acetamide ([(3)H]CI977) and [(3)H](2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl) propanoyl]amino]propanoyl]amino]acetyl]-methylamino]-N-(2-hydroxyethyl)-3-phenylpropanamide ([(3)H]DAMGO) binding to KOR and MOR receptors with ID(50) values of 2.0 and 8.6 mg/kg, respectively. An in vivo binding assay was developed using (-)-4-[(3)H]methoxycarbonyl-2-[(1-pyrrolidinylmethyl]-1-[(3,4-dichlorophenyl)acetyl]-piperidine ([(3)H]PF-04767135), a tritiated version of the KOR positron emission tomography ligand (-)-4-[(11)C]methoxycarbonyl-2-[(1-pyrrolidinylmethyl]-1-[(3,4-dichlorophenyl)acetyl]-piperidine ([(11)C]GR103545) in which PF-04455242 had an ID(50) of 5.2 mg/kg. PF-04455242 demonstrated antidepressant-like efficacy (mouse forced-swim test), attenuated the behavioral effects of stress (mouse social defeat stress assay), and showed therapeutic potential in treating reinstatement of extinguished cocaine-seeking behavior (mouse conditioned place preference). KOR agonist-induced plasma prolactin was investigated as a translatable mechanism biomarker. Spiradoline (0.32 mg/kg) significantly increased rat plasma prolactin levels from 1.9 ± 0.4 to 41.9 ± 4.9 ng/ml. PF-04455242 dose-dependently reduced the elevation of spiradoline-induced plasma prolactin with an ID(50) of 2.3 ± 0.1 mg/kg, which aligned well with the ED(50) values obtained from the rat in vivo binding and efficacy assays. These data provide further evidence that KOR antagonists have potential for the treatment of depression and addiction disorders.
Collapse
Affiliation(s)
- S Grimwood
- Neuroscience Research Unit, Pfizer Inc., Groton, CT 06340, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Verhoest PR, Basak AS, Parikh V, Hayward M, Kauffman GW, Paradis V, McHardy SF, McLean S, Grimwood S, Schmidt AW, Vanase-Frawley M, Freeman J, Van Deusen J, Cox L, Wong D, Liras S. Design and discovery of a selective small molecule κ opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242). J Med Chem 2011; 54:5868-77. [PMID: 21744827 DOI: 10.1021/jm2006035] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
By use of parallel chemistry coupled with physicochemical property design, a series of selective κ opioid antagonists have been discovered. The parallel chemistry strategy utilized key monomer building blocks to rapidly expand the desired SAR space. The potency and selectivity of the in vitro κ antagonism were confirmed in the tail-flick analgesia model. This model was used to build an exposure-response relationship between the κ K(i) and the free brain drug levels. This strategy identified 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242, which entered phase 1 clinical testing and has demonstrated target engagement in healthy volunteers.
Collapse
Affiliation(s)
- Patrick R Verhoest
- Neuroscience Medicinal Chemistry, Pfizer PharmaTherapeutics Research and Development, Groton, Connecticut, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
McAllister LA, Bechle BM, Dounay AB, Evrard E, Gan X, Ghosh S, Kim JY, Parikh VD, Tuttle JB, Verhoest PR. A general strategy for the synthesis of cyclic N-aryl hydroxamic acids via partial nitro group reduction. J Org Chem 2011; 76:3484-97. [PMID: 21452845 DOI: 10.1021/jo200530j] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We describe a generalized approach to stereocontrolled synthesis of substituted cyclic hydroxamic acids (3-amino-1-hydroxy-3,4-dihydroquinolinones) by selective reduction of substituted 2-nitrophenylalanine substrates. Compounds in this series have antibacterial properties and have also recently been reported as KAT II inhibitors. The key nitrophenyl alanine intermediates are prepared enantioselectively in excellent yield by phase transfer catalyzed alkylation of the corresponding nitrobenzyl bromides. The scope and limitations of the reductive cyclization transformation have been explored with attention to the effects of substitution pattern and electronics on reaction efficiency and byproduct formation. In addition, a novel activated trifluoroethyl ester cyclization strategy has been developed as an alternate approach to the most sterically demanding systems in this series.
Collapse
Affiliation(s)
- Laura A McAllister
- Neuroscience Chemistry, Pfizer Worldwide R&D, Eastern Point Rd., Groton, Connecticut 06340, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Wager TT, Villalobos A, Verhoest PR, Hou X, Shaffer CL. Strategies to optimize the brain availability of central nervous system drug candidates. Expert Opin Drug Discov 2011; 6:371-81. [DOI: 10.1517/17460441.2011.564158] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
36
|
Kleiman RJ, Lanz TA, Finley JE, Bove SE, Majchrzak MJ, Becker SL, Carvajal-Gonzales S, Kuhn AM, Wood KM, Mariga A, Nelson FR, Verhoest PR, Seymour PA, Stephenson DT. P3‐380: Dendritic spine density deficits in the hippocampal CA1 region of young Tg2576 mice are ameliorated with the PDE9A inhibitor PF‐04447943. Alzheimers Dement 2010. [DOI: 10.1016/j.jalz.2010.05.1922] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
| | | | | | | | | | | | | | - A. Max Kuhn
- Pfizer Global Research and DevelopmentGroton CT USA
| | | | | | | | | | | | | |
Collapse
|
37
|
Verhoest PR, Chapin DS, Corman M, Fonseca K, Harms JF, Hou X, Marr ES, Menniti FS, Nelson F, O'Connor R, Pandit J, Proulx-Lafrance C, Schmidt AW, Schmidt CJ, Suiciak JA, Liras S. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem 2010; 52:5188-96. [PMID: 19630403 DOI: 10.1021/jm900521k] [Citation(s) in RCA: 175] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
By utilizing structure-based drug design (SBDD) knowledge, a novel class of phosphodiesterase (PDE) 10A inhibitors was identified. The structure-based drug design efforts identified a unique "selectivity pocket" for PDE10A inhibitors, and interactions within this pocket allowed the design of highly selective and potent PDE10A inhibitors. Further optimization of brain penetration and drug-like properties led to the discovery of 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920). This PDE10A inhibitor is the first reported clinical entry for this mechanism in the treatment of schizophrenia.
Collapse
Affiliation(s)
- Patrick R Verhoest
- Neuroscience, Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Wager TT, Hou X, Verhoest PR, Villalobos A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci 2010; 1:435-49. [PMID: 22778837 DOI: 10.1021/cn100008c] [Citation(s) in RCA: 647] [Impact Index Per Article: 46.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2010] [Accepted: 03/02/2010] [Indexed: 11/30/2022] Open
Abstract
The interplay among commonly used physicochemical properties in drug design was examined and utilized to create a prospective design tool focused on the alignment of key druglike attributes. Using a set of six physicochemical parameters ((a) lipophilicity, calculated partition coefficient (ClogP); (b) calculated distribution coefficient at pH = 7.4 (ClogD); (c) molecular weight (MW); (d) topological polar surface area (TPSA); (e) number of hydrogen bond donors (HBD); (f) most basic center (pK(a))), a druglikeness central nervous system multiparameter optimization (CNS MPO) algorithm was built and applied to a set of marketed CNS drugs (N = 119) and Pfizer CNS candidates (N = 108), as well as to a large diversity set of Pfizer proprietary compounds (N = 11 303). The novel CNS MPO algorithm showed that 74% of marketed CNS drugs displayed a high CNS MPO score (MPO desirability score ≥ 4, using a scale of 0-6), in comparison to 60% of the Pfizer CNS candidates. This analysis suggests that this algorithm could potentially be used to identify compounds with a higher probability of successfully testing hypotheses in the clinic. In addition, a relationship between an increasing CNS MPO score and alignment of key in vitro attributes of drug discovery (favorable permeability, P-glycoprotein (P-gp) efflux, metabolic stability, and safety) was seen in the marketed CNS drug set, the Pfizer candidate set, and the Pfizer proprietary diversity set. The CNS MPO scoring function offers advantages over hard cutoffs or utilization of single parameters to optimize structure-activity relationships (SAR) by expanding medicinal chemistry design space through a holistic assessment approach. Based on six physicochemical properties commonly used by medicinal chemists, the CNS MPO function may be used prospectively at the design stage to accelerate the identification of compounds with increased probability of success.
Collapse
Affiliation(s)
- Travis T. Wager
- Neuroscience Medicinal Chemistry, Pfizer PharmaTherapeutics Research and Development, 558 Eastern Point Road, Groton, Connecticut 06340
| | - Xinjun Hou
- Neuroscience Medicinal Chemistry, Pfizer PharmaTherapeutics Research and Development, 558 Eastern Point Road, Groton, Connecticut 06340
| | - Patrick R. Verhoest
- Neuroscience Medicinal Chemistry, Pfizer PharmaTherapeutics Research and Development, 558 Eastern Point Road, Groton, Connecticut 06340
| | - Anabella Villalobos
- Neuroscience Medicinal Chemistry, Pfizer PharmaTherapeutics Research and Development, 558 Eastern Point Road, Groton, Connecticut 06340
| |
Collapse
|
39
|
Wager TT, Chandrasekaran RY, Hou X, Troutman MD, Verhoest PR, Villalobos A, Will Y. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem Neurosci 2010; 1:420-34. [PMID: 22778836 PMCID: PMC3368653 DOI: 10.1021/cn100007x] [Citation(s) in RCA: 321] [Impact Index Per Article: 22.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2010] [Accepted: 03/02/2010] [Indexed: 01/20/2023] Open
Abstract
As part of our effort to increase survival of drug candidates and to move our medicinal chemistry design to higher probability space for success in the Neuroscience therapeutic area, we embarked on a detailed study of the property space for a collection of central nervous system (CNS) molecules. We carried out a thorough analysis of properties for 119 marketed CNS drugs and a set of 108 Pfizer CNS candidates. In particular, we focused on understanding the relationships between physicochemical properties, in vitro ADME (absorption, distribution, metabolism, and elimination) attributes, primary pharmacology binding efficiencies, and in vitro safety data for these two sets of compounds. This scholarship provides guidance for the design of CNS molecules in a property space with increased probability of success and may lead to the identification of druglike candidates with favorable safety profiles that can successfully test hypotheses in the clinic.
Collapse
|
40
|
Verhoest PR, Proulx-Lafrance C, Corman M, Chenard L, Helal CJ, Hou X, Kleiman R, Liu S, Marr E, Menniti FS, Schmidt CJ, Vanase-Frawley M, Schmidt AW, Williams RD, Nelson FR, Fonseca KR, Liras S. Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy. J Med Chem 2010; 52:7946-9. [PMID: 19919087 DOI: 10.1021/jm9015334] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
By use of chemical enablement and prospective design, a novel series of selective, brain penetrant PDE9A inhibitors have been identified that are capable of producing in vivo elevations of brain cGMP.
Collapse
Affiliation(s)
- Patrick R Verhoest
- Neuroscience Chemistry, Pfizer Global Research and Development, Groton, CT 06340, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD, Williams RD, Verhoest PR, Menniti FS. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 2008; 325:681-90. [PMID: 18287214 DOI: 10.1124/jpet.107.132910] [Citation(s) in RCA: 230] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
We have recently proposed the hypothesis that inhibition of the cyclic nucleotide phosphodiesterase (PDE) 10A may represent a new pharmacological approach to the treatment of schizophrenia (Curr Opin Invest Drug 8:54-59, 2007). PDE10A is highly expressed in the medium spiny neurons of the mammalian striatum (Brain Res 985:113-126, 2003; J Histochem Cytochem 54:1205-1213, 2006; Neuroscience 139:597-607, 2006), where the enzyme is hypothesized to regulate both cAMP and cGMP signaling cascades to impact early signal processing in the corticostriatothalamic circuit (Neuropharmacology 51:374-385, 2006; Neuropharmacology 51:386-396, 2006). Our current understanding of the physiological role of PDE10A and the therapeutic utility of PDE10A inhibitors derives in part from studies with papaverine, the only pharmacological tool for this target extensively profiled to date. However, this agent has significant limitations in this regard, namely, relatively poor potency and selectivity and a very short exposure half-life after systemic administration. In the present report, we describe the discovery of a new class of PDE10A inhibitors exemplified by TP-10 (2-{4-[-pyridin-4-yl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymethyl}-quinoline succinic acid), an agent with greatly improved potency, selectivity, and pharmaceutical properties. These new pharmacological tools enabled studies that provide further evidence that inhibition of PDE10A represents an important new target for the treatment of schizophrenia and related disorders of basal ganglia function.
Collapse
Affiliation(s)
- C J Schmidt
- Neuroscience, Pfizer Global Research and Development, Pfizer, Inc., Eastern Point Road, Groton, CT 06340, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Abstract
A highly convergent, stereocontrolled total synthesis of the potent antiproliferative agent (+)-phorboxazole A (1) has been achieved. Highlights of the synthesis include: modified Petasis-Ferrier rearrangements for assembly of both the C(11-15) and C(22-26) cis-tetrahydropyran rings; extension of the Julia olefination to the synthesis of enol ethers; the design, synthesis, and application of a novel bifunctional oxazole linchpin; and Stille coupling of a C(28) trimethyl stannane with a C(29) oxazole triflate. The longest linear sequence leading to (+)-phorboxazole A (1) was 27 steps, with an overall yield of 3%.
Collapse
Affiliation(s)
- A B Smith
- Department of Chemistry, Monell Chemical Senses Center, University of Pennsylvania, Philadelphia, PA 19104, USA
| | | | | | | |
Collapse
|
43
|
Affiliation(s)
- A B Smith
- Department of Chemistry, Monell Chemical Senses Center and Laboratory for Research on the Structure of Matter University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | | | | | | |
Collapse
|
44
|
Smith AB, Minbiole KP, Verhoest PR, Beauchamp TJ. Phorboxazole synthetic studies. 2. Construction of a C(20-28) subtarget, a further extension of the Petasis-Ferrier rearrangement. Org Lett 1999; 1:913-6. [PMID: 10823222 DOI: 10.1021/ol990829m] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
[formula: see text] In this, the second of two Letters, we describe the efficient assembly of (+)-4, a C(20-28) subtarget for the total synthesis of phorboxazoles A (1) and B (2). The synthesis was achieved in 12 linear steps (20% overall yield) via Petasis-Ferrier rearrangement of an E/Z mixture of trisubstituted enol ethers (15) to assemble the C(22-26) cis-tetrahydropyran. A mechanism for the observed diastereoconvergence of 15 is proposed. In addition, a new tactic for the synthesis of enol ethers (e.g., 15) based on the elegant work of Julia is described.
Collapse
Affiliation(s)
- A B Smith
- Department of Chemistry, University of Pennsylvania, Philadelphia 19104, USA.
| | | | | | | |
Collapse
|
45
|
Smith AB, Verhoest PR, Minbiole KP, Lim JJ. Phorboxazole synthetic studies. 1. Construction of a C(3-19) subtarget exploiting an extension of the Petasis-Ferrier rearrangement. Org Lett 1999; 1:909-12. [PMID: 10823221 DOI: 10.1021/ol990830l] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
[formula: see text] In this, the first of two letters, we outline our overall strategy for the total synthesis of phorboxazoles A (1) and B (2), rare oxazole-containing macrolides possessing extraordinary antimitotic activity, and describe the assembly of a C(3-19) subtarget (-)-5 for the total synthesis of phorboxazole A. The synthesis of (-)-5 was achieved in 15 linear steps (12% overall yield), exploiting a modification of the Petasis-Ferrier rearrangement to construct the C(11-15) cis-tetrahydropyran. Dimethylaluminum chloride (Me2AlCl) proved to be the Lewis acid of choice for the Petasis-Ferrier rearrangement.
Collapse
Affiliation(s)
- A B Smith
- Department of Chemistry, University of Pennsylvania, Philadelphia 19104, USA.
| | | | | | | |
Collapse
|
46
|
Wu ES, Kover A, Loch JT, Rosenberg L, Semus SF, Verhoest PR, Gordon JC, Machulskis AC, McCreedy SA, Zongrone J, Blosser JC. Acylhydrazones as M1/M3 selective muscarinic agonists. Bioorg Med Chem Lett 1996. [DOI: 10.1016/0960-894x(96)00471-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
47
|
Macor JE, Ordway T, Smith RL, Verhoest PR, Mack RA. Synthesis and Use of 5-Vinyl-1,2,4-oxadiazoles as Michael Acceptors. A Rapid Synthesis of the Potent Muscarinic Agonist L-670,548. J Org Chem 1996. [DOI: 10.1021/jo9603340] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- John E. Macor
- Department of Chemistry, Astra Arcus USA, P.O. Box 20890, Rochester, New York 14602
| | - Timothy Ordway
- Department of Chemistry, Astra Arcus USA, P.O. Box 20890, Rochester, New York 14602
| | - Robert L. Smith
- Department of Chemistry, Astra Arcus USA, P.O. Box 20890, Rochester, New York 14602
| | - Patrick R. Verhoest
- Department of Chemistry, Astra Arcus USA, P.O. Box 20890, Rochester, New York 14602
| | - Robert A. Mack
- Department of Chemistry, Astra Arcus USA, P.O. Box 20890, Rochester, New York 14602
| |
Collapse
|